Group 1 - DexCom (DXCM) is outperforming its Medical peers with a year-to-date return of approximately 7.5%, while the average return for Medical companies is -2.9% [4] - DexCom is part of the Medical - Instruments industry, which has an average return of -7.5% this year, indicating that DXCM is performing better within its specific industry [5] - The Zacks Rank for DexCom is 2 (Buy), reflecting a positive earnings outlook with a 0.2% increase in the consensus estimate for full-year earnings over the past 90 days [3] Group 2 - Bayer Aktiengesellschaft (BAYRY) has also outperformed the sector with a year-to-date increase of 59.4% and holds a Zacks Rank of 2 (Buy) [4][5] - The consensus estimate for Bayer's current year EPS has risen by 6.4% over the last three months, indicating improving analyst sentiment [5] - Bayer is part of the Large Cap Pharmaceuticals industry, which is ranked 53 and has seen a slight decline of -0.3% this year [6]